Prommune, Inc.

Innovation in Immunotherapy

Prommune is a research and development company that has created a unique and patented means to safely and effectively awaken the body’s own natural immune defenses without inflammatory side-effects.  Such immune activation is possible through the use of novel immune stimulatory peptides, which are derived from a naturally-occurring protein component of the immune system.  The use of these host-derived immune stimulatory peptides provides a broad therapeutic platform enabling the treatment of normal and antibiotic-resistant infections and the rapid generation a huge variety of new vaccines for human and veterinary medicine.

EP67-Based Vaccines and Immunotherapies

Protective EP67-based vaccines made to:

  • Nicotine
  • Methamphetamine
  • Hepatitis B surface antigen
  • Human MUC1-glycoprotein
  • Large B cell lymphoma
  • Toxoplasma gondii
  • Cytomegalovirus
  • Coccidioides immitus (Valley Fever)


EP67-induced host-directed immunotherapy against:

  • MRSA dermal infection
  • MRSA biofilm (catheter) infection
  • Group B strep meningitis
  • Group B strep colonization on epithelial tissues
  • Toenail fungus (onychomycosis)

Vaccine Development

Because of the ability of EP67 to selectively engage/activate antigen presenting cells, EP67 can be used as a component in the design of vaccines.  A vaccine is rapidly made by the straightforward conjugation of EP67 to the surface of a protein antigen.  The EP67 moiety targets the protein antigen to and activates the antigen presenting cells such that the antigen is now effectively and properly presented to the lymphocyte population of immune cells, which generate the long-term memory immune responses against re-exposure to the pathogen that bears the protein against which the EP67-based vaccine was made.

Host-Directed Immune Therapy

Prommune’s lead immune simulatory peptide, EP67,  selectively engages and activates antigen presenting cells (monocytes, macrophages, dendritic cells) to induce the cellular and molecular elements associated with innate immunity – the body’s first line of immune defense against infection.  Once activated by EP67, these antigen presenting cells are primed to take up infective pathogens (bacteria, viruses, fungi) and destroy them via natural cellular mechanisms.  Thus, EP67 can be used to  awaken and direct the body’s own innate immune responses against infective pathogens – Host-Directed Immune Therapy (HDIT).  Importantly, the EP67-activated cellular processes for HDIT make no distinction between normal or antibiotic-resistant pathogens.  Thus, EP67-mediated HDIT can be used to fight normal as well as antibiotic-resistant infections and could be used as a complement to traditional antibiotics to deliver a powerful dual therapeutic assault on troublesome infections.

Breakthrough Research

A unique ability to safely and effectively activate the body’s own natural immune responses.

The Technology


A platform technology allowing for the development of a huge variety of vaccines, host-directed immunotherapy against normal and antibiotic-resistant infections, and enhancing the wound healing process.


Therapies being developed that utilize this platform technology in human and veterinary medicine.

Sam Sanderson, Ph.D.
Founder and Chairman
Sam Al-Murrani, Ph.D., MBA
Interim Chief Executive Officer
Kelly Lechtenberg, DVM, Ph.D.
Chief Medical Officer
Mark Hirschfeld, M.A.
Business Development


Write us via Email

9393 West 110th St.
51 Corporate Woods, Suite 500
Overland Park, KS 66210

Prommune, Inc. © 2017